Institution
Cancer Research Institute
Nonprofit•New York, New York, United States•
About: Cancer Research Institute is a nonprofit organization based out in New York, New York, United States. It is known for research contribution in the topics: Cancer & Population. The organization has 1061 authors who have published 754 publications receiving 26712 citations.
Topics: Cancer, Population, Breast cancer, Cell cycle, Gene
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Comparing the primary patterns of metastases and clinical outcomes between adenocarcinoma (Adenoca) and squamous cell carcinoma (SQ) in initially diagnosed stage IV non-small cell lung cancer (NSCLC) observed distinctive patterns of primary metastases.
14 citations
••
TL;DR: Pentoxifylline at sub-toxic doses lowers the level of activated FAK, Extracellular Regulated Kinase or Mitogen Activated Protein Kinase affecting cellular proliferation and survival and surely qualifies as a suitable prospect in the intervention of breast cancer.
14 citations
••
TL;DR: The results suggest that high expression of both IL17A and IL32 leads to enhancement of T cell responses in an inflammatory milieu that have been shown to be associated with better prognosis in ER-negative breast cancer.
Abstract: Pro-inflammatory cytokines such as Interleukin-17A (IL17A) and Interleukin-32 (IL32), known to enhance natural killer and T cell responses, are also elevated in human malignancies and linked to poor clinical outcomes. To address this paradox, we evaluated relation between IL17A and IL32 expression and other inflammation- and T cell response-associated genes in breast tumors. TaqMan-based gene expression analysis was carried out in seventy-eight breast tumors. The association between IL17A and IL32 transcript levels and T cell response genes, ER status as well as lymph node status was also examined in breast tumors from TCGA dataset. IL17A expression was detected in 32.7% ER-positive and 84.6% ER-negative tumors, with higher expression in the latter group (26.2 vs 7.1-fold, p < 0.01). ER-negative tumors also showed higher expression of IL32 as opposed to ER-positive tumors (8.7 vs 2.5-fold, p < 0.01). Expression of both IL17A and IL32 genes positively correlated with CCL5, GNLY, TBX21, IL21 and IL23 transcript levels (p < 0.01). Amongst ER-positive tumors, higher IL32 expression significantly correlated with lymph node metastases (p < 0.05). Conversely, in ER-negative subtype, high IL17A and IL32 expression was seen in patients with negative lymph node status (p < 0.05). Tumors with high IL32 and IL17A expression showed higher expression of TH1 response genes studied, an observation validated by similar analysis in the TCGA breast tumors (n=1041). Of note, these tumors were characterized by low expression of a potentially immunosuppressive isoform of IL32 (IL32γ). These results suggest that high expression of both IL17A and IL32 leads to enhancement of T cell responses. Our study, thus, provides basis for the emergence of strong T cell responses in an inflammatory milieu that have been shown to be associated with better prognosis in ER-negative breast cancer.
14 citations
••
13 citations
••
TL;DR: Results rule out the possibility of some other galectin taking over the function of galECTin-3 in gal-3(-/-) mice, and inhibition of N-glycosylation with Swainsonine (SW), which drastically reduces metastasis of B16F10 cells in Gal-3(+/+) mouse, did not affect lung metastasis when assessed in gal -3(-/+) mice.
13 citations
Authors
Showing all 1079 results
Name | H-index | Papers | Citations |
---|---|---|---|
Lewis L. Lanier | 159 | 554 | 86677 |
Xavier Estivill | 110 | 673 | 59568 |
Richard D. Kolodner | 105 | 307 | 40928 |
Jay A. Levy | 104 | 451 | 37920 |
Zbigniew Darzynkiewicz | 101 | 689 | 42625 |
Vikas P. Sukhatme | 100 | 317 | 39027 |
Israel Vlodavsky | 98 | 494 | 34150 |
Yung-Jue Bang | 94 | 664 | 46313 |
Naofumi Mukaida | 93 | 368 | 29652 |
Tetsuo Noda | 90 | 318 | 33195 |
George R. Pettit | 89 | 848 | 31759 |
Jo Vandesompele | 88 | 383 | 59368 |
Denis Gospodarowicz | 84 | 208 | 28915 |
Rolf Kiessling | 82 | 299 | 24617 |
Bruce R. Bistrian | 77 | 590 | 25634 |